

# The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study

NCT07464366

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	Ji Dongmei
<b>Enrollment</b>	90 participants

## Key Eligibility Criteria

---

### Inclusion (14)

- The subject must provide voluntary informed consent and agree to comply with all protocol requirements.
  - The subject must be at least 18 years of age on the date of informed consent form signing, with no restrictions based on gender.
  - Expected survival duration of at least 12 weeks.
  - Histopathologically confirmed recurrent or metastatic salivary gland cancer that cannot be treated with curative surgery or radiotherapy, including major subtypes such as adenoid cystic carcinoma, mucoepidermoid carcinoma, and adenocarcinoma; and immunohistochemically confirmed EGFR expression or positivity.
  - Patients diagnosed with adenoid cystic carcinoma (ACC) or acinic cell carcinoma must meet one of the following criteria: evidence of radiographic progression within 6 months prior to enrollment, or new or worsening tumor-related symptoms.
- ... and 9 more (see full listing online)

### Exclusion (23)

- A history of other malignancies within the past five years is exclusionary, except for adequately treated and cured cervical carcinoma in situ, thyroid cancer (excluding medullary or anaplastic types), or basal cell carcinoma of the skin.
  - Prior receipt of any of the following treatments:
  - Administration of an antibody-drug conjugate (ADC) with a monomethyl auristatin E (MMAE) payload within 3 months prior to first dose;
  - Exposure to any investigational agent in a clinical trial within 28 days prior to first dose;
  - Receipt of systemic anti-tumor therapy (including chemotherapy, radiotherapy, targeted therapy, or other modalities) within 28 days prior to first dose;
- ... and 18 more (see full listing online)

## Locations (1 total)

---

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China